Nicholas Forde
Family Medicine · Sacramento, CANPI 1821023862
Payments from drug & device makers
Across 135 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$614
- Lilly USA, LLC$303
- Merck$280
- Novo Nordisk$236
- Abbott$198
- GSK$154
- plus $961 from 21 others
What the payments were for
- Food & beverage$2,746100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 24 | $614 |
| Lilly USA, LLC | 18 | $303 |
| Merck | 16 | $280 |
| Novo Nordisk | 13 | $236 |
| Abbott | 9 | $198 |
| GSK | 7 | $154 |
| Boehringer Ingelheim | 7 | $128 |
| AstraZeneca | 7 | $118 |
| Johnson & Johnson | 5 | $87 |
| Sanofi Pasteur Inc. | 2 | $65 |
| Bayer | 2 | $58 |
| Dexcom, Inc. | 2 | $56 |
| Amarin Pharma, Inc. | 3 | $54 |
| Sanofi-aventis U.S. LLC | 4 | $53 |
| Sobi, Inc | 2 | $44 |
| Pfizer | 2 | $37 |
| Tandem Diabetes Care, Inc. | 1 | $37 |
| Phadia US Inc. | 2 | $36 |
| Exact Sciences | 1 | $31 |
| Novartis | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Alkermes, Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Cranial Technologies, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vemlidy$124
How this compares
$2,746 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 95 | $93,631 |
| JanuviaSitagliptin Phosphate | 91 | $81,699 |
| TradjentaLinagliptin | 92 | $57,464 |
| OzempicSemaglutide | 49 | $52,729 |
| EliquisApixaban | 31 | $47,915 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 77 | $35,014 |
| TrulicityDulaglutide | 30 | $32,533 |
| VemlidyTenofovir Alafenamide | 20 | $25,806 |
| Breo ElliptaFluticasone/Vilanterol | 51 | $25,415 |
| Spiriva RespimatTiotropium Bromide | 29 | $24,271 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $14,840 |
| SynjardyEmpagliflozin/Metformin Hcl | 16 | $12,065 |
| Bydureon BciseExenatide Microspheres | 16 | $11,718 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $8,226 |
| BrilintaTicagrelor | 14 | $8,145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Synjardy | $128 | $187,431232 claims |
| MerckJanuvia, Janumet | $280 | $89,925102 claims |
| Novo NordiskOzempic | $236 | $52,72949 claims |
| PfizerEliquis | $37 | $47,91531 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $154 | $46,91996 claims |
| Lilly USA, LLCTrulicity | $303 | $32,53330 claims |
| GileadVemlidy | $614 | $25,80620 claims |
| AstraZenecaBrilinta | $118 | $8,14514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Sacramento
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.